Akwai jayayya da yawa game da ko magungunan magungunan da ake kira "anti-epileptic" magunguna ne abin da ake kira "magungunan likita." A wasu kalmomi, akwai wasu tambayoyi ko magungunan magungunan magunguna suke aiki tare da takwarorinsu masu yawa masu daraja. Idan kana tunanin canzawa daga magungunan miyagun ƙwayoyi zuwa magani na kwayoyin cuta, ko ma idan kuna la'akari da sauyawa daga kwayar cutar daya zuwa wani, kuna buƙatar ku zama sananne game da wannan batu don ku yanke shawara.
Hakika, za ku so ku tabbatar da tattauna wannan shawara tare da likita.
Ta yaya Magungunan Magungunan Kuɗi suka zo cikin Play
Lokacin da kamfanonin ƙwayoyi suka taso da sababbin sababbin magunguna, sukan sauke miliyoyin dolar Amirka zuwa bincike. Wannan tsari mai mahimmanci na taimakawa wajen tabbatar da cewa magani yana dace da ka'idodi masu dacewa don aminci da tasiri. Ƙungiyar miyagun ƙwayoyi za ta iya tabbatar da cajin kudi mai yawa don sabon magani. Kimanin shekaru 20 bayan da aka ba da takardar shaidar farko, kamfanin na asibiti ya yi hasarar kawai don rarraba wannan magani. A wasu kalmomi, wasu kamfanoni zasu iya ba da wata magungunan magani a farashin ƙananan.
Cibiyar Abinci da Drugke ta Amurka ta jarraba dukkanin maganin maganin antiepileptics don tabbatar da cewa magunguna suna hulɗa da kayayyakin samfurori. Duk da haka, binciken bincike na likita da rahotanni sun nuna cewa akwai matsala masu yawa yayin sauyawa daga maganin antiepileptic zuwa kwayoyin halitta.
Idan FDA ta kasance mai gwadawa a gwada, to yaya zai yiwu likitoci da marasa lafiya da yawa suna nuna damuwa?
Damuwa a Sauyawa
FDA ta yi la'akari da maganin miyagun ƙwayoyi don zama "mahimmanci daidai" ga miyagun ƙwayoyi iri ɗaya idan yana da nauyin adadin mai aiki, kuma ya sadu da ma'auni don ƙarfin, ingancin, tsarkaka, da kuma ainihi.
Abubuwa biyu sunyi nazari sosai:
- Ƙungiya-karkashin-da-layi (AUC)
- Matsakaicin ƙaddamar da ƙwayar plasma (Cmax).
Wadannan siffofi suna kimantawa yadda yawancin magani ke shawo cikin jini. FDA na buƙatar cewa AUC da Cmax na maganin maye gurbin su na cikin kashi 80 zuwa kashi 125 cikin 100 na nau'ikan ma'auni da kashi 90 bisa dari. Wannan yana kama da kyawawan gefe, musamman ma idan miyagun ƙwayoyi ke tambaya yana da ƙananan "farfadowa na asibiti" - bambancin tsakanin kwayar magani da ke da tasiri da kuma maganin maganin maganin magani wanda zai haifar da sakamako mai tasiri.
Bugu da ƙari, gwaje-gwaje don tabbatar da cewa kwayoyin kwayoyi sun hadu da wannan daidaitattun suna yawanci akan kimanin mutane 35. Wannan ya bambanta fiye da sau da yawa daruruwan mutane da aka jarraba don maganin miyagun ƙwayoyi.
Menene Gwamnatin Tarayya ta FDA Game da Sauyawa zuwa Magungunan Jigilar Hoto?
FDA ta bayyana cewa babu wata hujja mai shaida cewa akwai haɓaka da yawa na sauyawa zuwa kwayoyin halitta. Wadansu magoya bayan wannan matsayi sun nuna cewa tasirin da aka samu a cikin wani abu zai iya taka rawar a cikin matsalolin da marasa lafiya suka bayar. Ganin cewa sakamakon wurin zai shafi lafiyar marasa lafiyar ingantacciyar cigaba bayan sun sami wani abu marar amfani (kamar kwayar sukari) saboda mai haƙuri ya yi imanin cewa abu zai taimaka musu, wani sakamako na hakika ya shafi alamun marasa lafiya wanda ke ci gaba da muni saboda suna ganin magani mai karfi ba zai taimaka ba.
Yana da wuya a faɗi - watakila damuwa da damuwa da ke haɗuwa da sauyawa zuwa wani abu da ke haifar da kamawa a wasu mutane tare da epilepsy.
Binciken Ƙarƙashin Ƙarƙashin Ƙarƙwarar Magunguna
Duk da haka, idan rashin tasiri yana da alaka da damuwa na magunguna, yana da banbanci cewa irin wannan sakamako ba a gani a wasu nau'ikan kwayoyi kamar maganin jinya . Me yasa hakan zai kasance mafi matsala a marasa lafiya ɗauke shan magani don epilepsy? Yana iya zama kawai cewa masu maganin rigakafi suna buƙatar ƙaddamar da kashi sosai kuma cewa sigogi da FDA ta kafa ba sa aiki da magunguna tare da windows windows warkewa.
A wannan yanayin, matsala ita ce ta sauyawa daga sunan sunaye zuwa magani na kwayar halitta, amma kuma yana iya kasancewa a yayin sauyawa daga ɗayan ɗayan zuwa wani, kamar yadda waɗannan asoshin zasu iya bambanta. Alal misali, idan magani guda daya yana da kashi 125 cikin kashi mai mahimmanci da aka samo a cikin sunan mai suna anti-epileptic, kuma idan kun canza zuwa magani wanda yana da kashi 80 cikin kashi na kashi, kashi na likitan ku ya faɗi sosai.
Risks mai yiwuwa
Hadarin da za a canza daga sunan sunaye zuwa jinsin ko tsakanin kwayoyin halitta zai dogara ne a kan abin da ake daukar magunguna. Magunguna da ke amfani da Keppra (levetiracetam), Lamictal (lamotrigine) ko Divalproex suna iya canzawa daga jigilar jini zuwa alamun samfurori, sau da yawa don ƙarar haɗari ko canji a cikin halayen maganin ƙeta. Ana kuma kira karin ƙwaƙwalwar lokacin da aka kama wani abu mai hatsarin gaske, irin su tare da mutanen da suke kora, suna da ciki, ko kuma waɗanda suka sha wahala sakamakon sakamakon su a baya.
Layin Ƙasa
Matsalar da aka ruwaito tare da canzawa daga sunan magungunan maganin antiepileptic ba yana nufin cewa duk wani maganin anti-epileptic ya kamata a kauce masa. Kamar kowane magani, akwai yiwuwar hadari da kuma amfani ga sauyawa zuwa kwayoyin halitta. Wadannan halayen da wadata suna buƙatar fahimtar su kafin yin yanke shawara su canza. Za a sami kuɗin kuɗi, amma akwai wasu matsalolin da kuke buƙatar ku sani ko gyaran gyare-gyaren da za a buƙaci. Yana da muhimmanci a gane yiwuwar rikitarwa har ma a lokacin da kunna tsakanin magungunan kwayoyi da kuma tattauna duk abin da kuka zaba da damuwa tare da likitanku.
Sources:
Ƙungiyar Harkokin Cutar Agaji na Amurka (AES) ta 65th: Gidan taro na garin na FDA. Gabatar da Disamba 2, 2011.
Gidal, BE (2012). Magunguna masu maganin antilepileptic: Yaya kyau ya isa? Kogin Wuta, 12 (1): 32-34.
Henney, JE. (1999). Daga abinci da miyagun ƙwayoyi. JAMA, 282 1995.
Kramer, G., Steinhoff, BJ, Feucht, M., Pfafflin, M., & May, TW (2007). Kwarewa tare da kwayoyi masu magunguna a marasa lafiya marasa lafiya: nazarin lantarki na mambobi na Jamus, Austrian da Swiss branches na ILAE. Epilepsia , 48 (3): 609-611
Krauss, GJ, Caffo, B., Chang, Y.-T., Hendrix, CW, & Chuang, K. (2011). Bada la'akari da yawan kwayoyin halitta na kwayoyin cutar antiepilepsy. Annals of Neurology , 70: 221-228. Doi: 10.1002 / ana.22452
DISCLAIMER: Bayanin ilimi a wannan shafin shine don dalilai na ilimi kawai. Bai kamata a yi amfani dashi don maye gurbin kulawa ta sirri daga likitan lasisi. Don Allah a ga likitan ku don ganewar asali da kuma maganin duk wani abu game da bayyanar cututtuka ko yanayin kiwon lafiya .